ECSP22077299A - Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades asociadas con modulación del pi3k - Google Patents

Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades asociadas con modulación del pi3k

Info

Publication number
ECSP22077299A
ECSP22077299A ECSENADI202277299A ECDI202277299A ECSP22077299A EC SP22077299 A ECSP22077299 A EC SP22077299A EC SENADI202277299 A ECSENADI202277299 A EC SENADI202277299A EC DI202277299 A ECDI202277299 A EC DI202277299A EC SP22077299 A ECSP22077299 A EC SP22077299A
Authority
EC
Ecuador
Prior art keywords
pi3k
phosphoinositide
kinase
modulation
treatment
Prior art date
Application number
ECSENADI202277299A
Other languages
English (en)
Inventor
David L Mcelligott
Daniel Lee Severance
Thomas Combs Irvin
Katelyn Frances Long
Johnathan Alexander Mclean
Manoj Kumar
Gabrielle R Kolakowski
Michael Brian Welch
Aleksey I Gerasyuto
Loredana Puca
Eugene R Hickey
Nicholas A Boyles
Kannan Karukurichi Ravi
Jennifer Lynn Knight
Tien Widjaja
Anke Klippel-Giese
Edward A Kesicki
Sean Douglas Aronow
Markus K Dahlgren
Shulu Feng
Erin Danielle Anderson
Christopher Glenn Mayne
Original Assignee
Petra Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Petra Pharma Corp filed Critical Petra Pharma Corp
Publication of ECSP22077299A publication Critical patent/ECSP22077299A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La descripción se refiere a los compuestos de la Fórmula (I) como inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (PI3K) útiles en el tratamiento de enfermedades o trastornos asociados con la modulación del PI3K, Fórmula (I): o un profármaco, solvato, enantiómero, estereoisómero, tautómero o sal farmacéuticamente aceptable de este, en donde R1, R2, R3, R4, R5, R6, R7, R8, R9, W, X, Y, s, y el Anillo A son como se describen en la presente descripción.
ECSENADI202277299A 2020-04-03 2022-10-03 Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades asociadas con modulación del pi3k ECSP22077299A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063005096P 2020-04-03 2020-04-03

Publications (1)

Publication Number Publication Date
ECSP22077299A true ECSP22077299A (es) 2023-01-31

Family

ID=75674963

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202277299A ECSP22077299A (es) 2020-04-03 2022-10-03 Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades asociadas con modulación del pi3k

Country Status (18)

Country Link
US (2) US11649227B2 (es)
EP (1) EP4126851A1 (es)
JP (1) JP7505023B2 (es)
KR (1) KR102857816B1 (es)
CN (1) CN115956075B (es)
AR (1) AR121719A1 (es)
AU (1) AU2021248415B2 (es)
BR (1) BR112022019918A2 (es)
CO (1) CO2022014160A2 (es)
CR (1) CR20220493A (es)
EC (1) ECSP22077299A (es)
IL (1) IL296918A (es)
JO (1) JOP20220247A1 (es)
MX (1) MX2022012306A (es)
PE (1) PE20230824A1 (es)
PH (1) PH12022552637A1 (es)
TW (1) TWI794780B (es)
WO (1) WO2021202964A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR121719A1 (es) 2020-04-03 2022-06-29 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
MX2023013082A (es) * 2021-05-03 2024-01-08 Petra Pharma Corp Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades.
CR20230517A (es) 2021-05-03 2023-11-28 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
AU2022282380B2 (en) * 2021-05-27 2025-08-14 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of cancer
TW202329930A (zh) 2021-09-30 2023-08-01 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑
WO2023060262A1 (en) * 2021-10-07 2023-04-13 Relay Therapeutics, Inc. Pi3k-alpha inhibitors and methods of use thereof
TW202334137A (zh) * 2021-11-03 2023-09-01 美商薩諾管理公司 Ｐｉ３ｋ抑制劑及治療癌症之方法
WO2023104111A1 (en) * 2021-12-08 2023-06-15 Nanjing Zenshine Pharmaceuticals Co., Ltd. Fused heterocyclic compounds as pi3kalpha inhibitors
CA3240772A1 (en) * 2021-12-22 2023-06-29 Kevan M. Shokat Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase
US20240124422A1 (en) * 2022-03-29 2024-04-18 Prelude Therapeutics Incorporated Mutant pi3k-alpha inhibitors and their use as pharmaceuticals
WO2023205680A1 (en) * 2022-04-20 2023-10-26 Synnovation Therapeutics, Inc. PI3Kα INHIBITORS
US20250263394A1 (en) * 2022-04-24 2025-08-21 InventisBio Co., Ltd. Compounds, preparation methods and uses thereof
CN119301106A (zh) * 2022-04-29 2025-01-10 佩特拉制药公司 用于治疗疾病的磷酸肌醇3-激酶(pi3k)的变构苯并吡喃酮抑制剂
US20250313524A1 (en) * 2022-05-10 2025-10-09 Relay Therapeutics, Inc. Pi3k-alpha inhibitors and methods of use thereof
AU2023283727A1 (en) 2022-06-08 2024-12-12 Onkure, Inc. Benzopyrimidin-4(3h)-ones as pi3k inhibitors
CN117384124B (zh) * 2022-07-04 2025-08-01 安徽中医药大学 Hdac抑制剂、组合物及其应用
CN117362281A (zh) * 2022-07-07 2024-01-09 海创药业股份有限公司 一种pi3k抑制剂及其制备方法和用途
IL319246A (en) 2022-09-08 2025-04-01 Onkure Inc Isoquinolones as PI3K inhibitors
CN119894898A (zh) * 2022-09-09 2025-04-25 益方生物科技(上海)股份有限公司 化合物、其制备方法和用途
WO2024064024A1 (en) 2022-09-19 2024-03-28 Onkure, Inc. ((4-oxo-3,4-dihydroquinazolin-8-yl)methyl)amine derivatives as p13k inhibitors for the treatment of cancer
WO2024081345A1 (en) 2022-10-14 2024-04-18 Onkure, Inc. Benzopyrimidin-4(3h)-ones as pi3k inhibitors
EP4602031A1 (en) * 2022-10-14 2025-08-20 Genesis Therapeutics, Inc. Methods for treating cancer
WO2024086789A2 (en) * 2022-10-20 2024-04-25 Prelude Therapeutics Incorporated Mutant pi3k-alpha inhibitors and their use as pharmaceuticals
KR20250109699A (ko) * 2022-11-01 2025-07-17 페트라 파마 코포레이션 질환의 치료를 위한 포스포이노시티드 3-키나제 (pi3k)의 알로스테릭 크로메논 억제제
IL320602A (en) 2022-11-02 2025-07-01 Petra Pharma Corp Targeting allosteric and orthosteric pockets of phosphoinositide 3-kinase (pi3k) for the treatment of disease
KR20250097960A (ko) * 2022-11-02 2025-06-30 페트라 파마 코포레이션 질환의 치료를 위한 포스포이노시티드 3-키나제 (pi3k)의 알로스테릭 크로메논 억제제
WO2024099437A1 (en) * 2022-11-11 2024-05-16 Fochon Biosciences, Ltd. Compounds as protein kinase inhibitors
WO2024163752A1 (en) * 2023-02-02 2024-08-08 Synnovation Therapeutics, Inc. HETEROCYCLIC COMPOUNDS AS PI3Kα INHIBITORS
AU2024234319A1 (en) * 2023-03-15 2025-10-02 An2 Therapeutics, Inc. Chemical compounds
WO2024211346A1 (en) * 2023-04-03 2024-10-10 Prelude Therapeutics Incorporated Mutant pi3k-alpha inhibitors and their use as pharmaceuticals
KR20260005985A (ko) 2023-05-05 2026-01-12 일라이 릴리 앤드 캄파니 Er+ 유방암을 갖는 대상체에서 중추 신경계 (cns) 전이를 치료 및 예방하는 데 사용하기 위한 임루네스트란트 또는 그의 염
WO2024260464A1 (en) * 2023-06-21 2024-12-26 Regor Pharmaceuticals, Inc. Pi3k inhibitors and use thereof
WO2025007074A1 (en) * 2023-06-30 2025-01-02 Reactive Biosciences, Inc. Chemical compounds
CN119431297A (zh) * 2023-08-02 2025-02-14 郑州同源康医药有限公司 稠环类化合物及其用途
AU2024325407A1 (en) 2023-08-11 2026-02-19 Onkure Therapeutics, Inc. Benzopyridinones and benzopyrimidinones as pi3k inhibitors
WO2025042896A1 (en) * 2023-08-22 2025-02-27 Mayo Foundation For Medical Education And Research DNA TOPOISOMERASE IIβ INHIBITORS
CN119874676A (zh) * 2023-10-25 2025-04-25 海创药业股份有限公司 一种pi3k抑制剂及其制备方法和用途
WO2025207755A1 (en) 2024-03-29 2025-10-02 Onkure, Inc. Quinolizinones as pi3k inhibitors
WO2025212360A1 (en) 2024-04-01 2025-10-09 Onkure, Inc. Isoquinolones as pi3k inhibitors
WO2025231052A1 (en) * 2024-05-01 2025-11-06 Petra Pharma Corporation Solid dispersions of 6-chloro-3-[(1r)-1-[3,6-dimethyl-2-(2- methylindazol-5-yl)-4-oxo-chromen-8-yl]ethoxy]pyridine-2-carboxamide
WO2025231053A1 (en) * 2024-05-01 2025-11-06 Petra Pharma Corporation Solid forms of 6-chloro-3-[(1r)-1-[3,6-dimethyl-2-(2-methylindazol-5-yl)-4-oxo-chromen-8-yl]ethoxy]pyridine-2-carboxamide
WO2025255233A1 (en) 2024-06-07 2025-12-11 Onkure, Inc. Compounds containing fused tricyclic rings as pi3k inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1190405B (it) 1985-10-22 1988-02-16 Recordati Chem Pharm Derivati del flavone
IL89840A (en) 1988-04-06 1996-10-31 Lipha Substituted flavonoid compounds and salts thereof their preparation and pharmaceutical composition containing them
RU2118321C1 (ru) 1988-12-21 1998-08-27 Дзе Апджон Компани Замещенные бензопираноны и их фармацевтически приемлемые соли и гидраты
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
AU2001230426C1 (en) 2000-01-24 2006-06-22 Astrazeneca Ab Therapeutic morpholino-substituted compounds
US20030105073A1 (en) * 2001-10-23 2003-06-05 Haughan Alan Findlay Quinolone derivatives
US7884127B2 (en) 2002-07-08 2011-02-08 Pirimal Life Sciences Ltd. Inhibitors of cyclin dependent kinases and their use
TWI331034B (en) 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
NZ538420A (en) 2002-08-16 2007-06-29 Kinacia Pty Ltd Inhibition of phosphoinositide 3-kinase beta
CN101260104A (zh) * 2002-08-16 2008-09-10 阿斯利康(瑞典)有限公司 抑制磷酸肌醇3-激酶β
CN102227420B (zh) 2008-09-29 2015-06-24 西特里斯药业公司 作为沉默调节蛋白调节剂的喹唑啉酮、喹诺酮和相关的类似物
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
PT2496567T (pt) * 2009-11-05 2017-11-15 Rhizen Pharmaceuticals S A Novos moduladores de quinase benzopiran
US8530470B2 (en) * 2011-04-13 2013-09-10 Astrazeneca Ab Chromenone derivatives
CN106008479B (zh) * 2015-03-06 2020-01-10 南京圣和药业股份有限公司 作为磷脂酰肌醇3-激酶δ抑制剂的取代嘧啶类化合物及其应用
CA3017366A1 (en) 2016-03-11 2017-09-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Icariin and icaritin derivatives
CN108299365B (zh) 2018-01-31 2021-08-06 中南大学 一种黄酮衍生物及其应用
AR121719A1 (es) * 2020-04-03 2022-06-29 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades

Also Published As

Publication number Publication date
TW202200567A (zh) 2022-01-01
WO2021202964A1 (en) 2021-10-07
PH12022552637A1 (en) 2023-01-16
KR20220163462A (ko) 2022-12-09
CO2022014160A2 (es) 2023-02-16
JOP20220247A1 (ar) 2023-01-30
EP4126851A1 (en) 2023-02-08
US20230286960A1 (en) 2023-09-14
US20220372023A1 (en) 2022-11-24
CA3173569A1 (en) 2021-10-07
BR112022019918A2 (pt) 2023-02-14
KR102857816B1 (ko) 2025-09-11
PE20230824A1 (es) 2023-05-19
TWI794780B (zh) 2023-03-01
AR121719A1 (es) 2022-06-29
AU2021248415B2 (en) 2024-03-21
JP7505023B2 (ja) 2024-06-24
MX2022012306A (es) 2023-01-04
AU2021248415A1 (en) 2022-10-20
JP2023521321A (ja) 2023-05-24
US11649227B2 (en) 2023-05-16
CR20220493A (es) 2022-12-15
IL296918A (en) 2022-12-01
CN115956075A (zh) 2023-04-11
CN115956075B (zh) 2025-11-07

Similar Documents

Publication Publication Date Title
ECSP22077299A (es) Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades asociadas con modulación del pi3k
DOP2023000245A (es) Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
MX2024003721A (es) Inhibidores alostericos de cromenona de la fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades.
MX2023013987A (es) Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento contra el cáncer.
CL2022001739A1 (es) Compuestos tricíclicos sustituidos
DOP2025000245A (es) Inhibidores de kras
MX2023001876A (es) Derivados de rapamicina.
MX394700B (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos.
CO2019000932A2 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
CL2021000844A1 (es) Compuestos de indolinona para uso como inhibidores de map4k1
UY35551A (es) Derivados heteroarilos como inhibidores de aldosterona sintasa
AR115731A1 (es) Derivados de pirrolo[1,2-b]piridazina como inhibidores de quinasas irak4
CO2020010306A2 (es) Compuestos de sulfonimidoilpurinona 7-sustituida y derivados para el tratamiento y profilaxis de cáncer de hígado.
CL2022002975A1 (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
CO2025003099A2 (es) Compuestos para el tratamiento del cáncer
MX2024003028A (es) Derivados de 6 aza quinolina y usos relacionados.
CO2025011377A2 (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
CL2025002151A1 (es) Derivados de fenilpiperidina como inhibidores de la glutaminil-péptido ciclotransferasa y proteína similar a glutaminil-péptido ciclotransferasa
MX2025005073A (es) Inhibidores alostericos de cromenona de la fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades
CL2022002697A1 (es) Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
AR131413A1 (es) Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso
AR131414A1 (es) Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso
AR130937A1 (es) Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
AR125979A1 (es) Inhibidores alostéricos de cromenona de la fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades
AR125742A1 (es) Inhibidores alostéricos de cromenona de la fosfoinositida 3-quina6sa (pi3k) para el tratamiento de enfermedades